Nebu-Flow announced it had raised an additional $5.9 million of investment to accelerate the next generation of inhaled drugs for patients with respiratory disorders, which are the main cause of death and disability worldwide. The company’s nebulizer platform has been developed to provide several advantages over existing technologies. Overall, the worldwide inhalable drug market was valued at about $33 billion in 2023, with the nebulizer market at over $1 billion.
This funding round was led by SCVC (a leading UK-based venture capital firm that invests in early-stage deep tech spinouts). And Scottish Enterprise, Foresight WAE Technology, SIS Ventures, Ascension, and Conduit EIS Impact Fund also joined the round.
KEY QUOTES:
“Our mission is to revolutionize respiratory drug delivery. The investment accelerates our development activities to position the company for inhalation delivery of RNA-based formulations. We now look forward to the final product development and commercialization stages, with the support of SCVC and our other investors.”
- Dr. Elijah Nazarzadeh, CEO and co-founder of Nebu-Flow
“Essentially, our technology provides new opportunities for targeted drug delivery to the lungs as well as drug delivery to the cardiovascular and central nervous systems. We are engaged with a number of partners in the UK and North America who are currently trialing the product as we prepare for the regulatory approval stage.”
- Dr Elijah Nazarzadeh
“We are deeply impressed by the team’s achievement of its technical and commercial milestones to date, demonstrating their capability and readiness for the next phase in healthcare innovation. This investment underscores our confidence in Nebu-Flow’s groundbreaking nebulization technology, which is poised to transform respiratory drug delivery, improve health and deliver impact.”
- Dr. Harry Destecroix, Managing Partner, SCVC
